期刊文献+

贝伐珠单抗致恶性卵巢癌患者肠道穿孔1例并文献复习 被引量:1

Intestinal Perforation Caused by Bevacizumab in Patients with Ovarian Cancer:A Case Report and Literature Review
原文传递
导出
摘要 1例36岁恶性卵巢癌患者2021年7月3日于某院行紫杉醇+卡铂+贝伐珠单抗新辅助化疗,化疗3疗程后考虑效果欠佳改为多柔比星+卡铂+贝伐珠单抗化疗3次,合计6次。2021年12月3日患者出现腹腔引流液浑浊呈粪渣样,伴恶臭。腹部CT显示大量气腹,弥漫性腹膜炎改变,考虑肠道穿孔,急诊行剖腹探查术,术中见左侧横结肠近脾曲约20 cm处可见一个沿肠管长轴平行的全层破口,关闭结肠破口,行结肠造口+腹腔粘连松解+腹腔置管引流术。术后抗感染对症治疗44 d后,病情稳定顺利出院。肠穿孔为贝伐珠单抗严重不良反应,该患者肠穿孔的出现与贝伐珠单抗的使用存在时间相关性,肠道穿孔很可能为贝伐珠单抗不良反应。 A 36-year-old patient with ovarian cancer received neoadjuvant chemotherapy of paclitaxel+carboplatin+bevacizumab on July 3,2021.After three courses of chemotherapy,considering the poor effect,chemotherapy was changed to doxorubicin+carboplatin+bevacizumab,a total of 6 times.On December 3,2021,the abdominal drainage fluid of the patient presented turbidity with fecal residue and foul odor.Abdominal CT showed extensive pneumoperitoneum with diffuse peritonitis changes,which suggested intestinal perforation.Emergency exploratory laparotomy was performed,a full-layer tear parallel to the long axis of the bowel was observed at about 20 cm near the splenic flexure of the left transverse colon.The colon laceration was closed,and colostomy,abdominal adhesion release,peritoneal tube drainage was performed.After treatment of 44 days,the patient was on the mend and discharged.Serious gastrointestinal perforation had occurred with bevacizumab.There was a time correlation between the occurence of intestinal perforation and the use of bevacizumab in the patient.This intestinal perforation is likely adverse reaction of bevacizumab.
作者 蓝燕 殷锦锦 梅峥嵘 LAN Yan;YIN Jinjin;MEI Zhengrong(Department of Pharmacy,Key Laboratory for Major Obstetric Diseases of Guangdong Province,The Third Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510150,China;Maternal and Child Health Care Family Planning Service Center in Zhanjiang,Zhanjiang,Guangdong 524033,China)
出处 《今日药学》 CAS 2022年第5期397-400,共4页 Pharmacy Today
基金 广东省医院药学研究基金(2021A29)。
关键词 贝伐珠单抗 不良反应 肠道穿孔 bevacizumab adverse drug reaction intestinal perforation
  • 相关文献

参考文献7

二级参考文献78

  • 1凌小婷,徐国才,林荣春,谢玲玲,李晶,林仲秋.晚期卵巢癌腹腔化疗联合静脉化疗用于新辅助化疗Ⅰ期临床试验研究[J].中国实用妇科与产科杂志,2019,0(12):1345-1349. 被引量:12
  • 2张萌萌,陈森,翟所迪.贝伐珠单抗相关性肠穿孔:病例报道与文献综述[J].临床药物治疗杂志,2014,12(S01):57-60. 被引量:2
  • 3Rebecca Siegel,Deepa Naishadham,Ahmedin Jemal.Cancer statistics, 2013[J]. CA: A Cancer Journal for Clinicians . 2013 (1)
  • 4Marta Vives,Mireia M. Ginestà,Kristina Gracova,Mariona Graupera,Oriol Casanovas,Gabriel Capellà,Teresa Serrano,Berta Laquente,Francesc Vi?als.Metronomic chemotherapy following the maximum tolerated dose is an effective anti‐tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells[J]. Int. J. Cancer . 2013 (10)
  • 5Robert M. Wenham,James Lapolla,Hui-Yi Lin,Sachin M. Apte,Johnathan M. Lancaster,Patricia L. Judson,Jesus Gonzalez-Bosquet,Amber Herschberger,Laura J. Havrilesky,Angeles Alvarez Secord.A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy[J]. Gynecologic Oncology . 2013 (1)
  • 6Marcela G. del Carmen,John Micha,Laurie Small,Daron G. Street,Anil Londhe,Tracy McGowan.A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer[J]. Gynecologic Oncology . 2012 (3)
  • 7Ursula A. Matulonis,Lauren Pereira,Joyce Liu,Hang Lee,Julie Lee,Christin Whalen,Susana Campos,Tina Atkinson,Margaret Hill,Suzanne Berlin.Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer[J]. Gynecologic Oncology . 2012 (1)
  • 8Todd D. Tillmanns,M. Patrick Lowe,Mark S. Walker,Edward J. Stepanski,Lee S. Schwartzberg.Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma[J]. Gynecologic Oncology . 2012
  • 9Carol Aghajanian,Stephanie V. Blank,Barbara A. Goff,Patricia L. Judson,Michael G. Teneriello,Amreen Husain,Mika A. Sovak,Jing Yi,Lawrence R. Nycum.OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer[J]. Journal of Clinical Oncology . 2012 (17)
  • 10Kazuya Kudoh,Masashi Takano,Hiroko Kouta,Ryoko Kikuchi,Tsunekazu Kita,Morikazu Miyamoto,Akio Watanabe,Masafumi Kato,Tomoko Goto,Yoshihiro Kikuchi.Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers[J]. Gynecologic Oncology . 2011 (2)

共引文献52

同被引文献26

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部